ライフサイエンスコーパス: hemorrhagic complication

1 ulopathy characterized by thromboembolic and hemorrhagic complications.

2 pplied to predict severe maternal outcome in hemorrhagic complications.

3 ney transplantation (KT) outcomes in case of hemorrhagic complications.

4 13%) patients but there was no PP-related or hemorrhagic complications.

5 in prothrombin times, and in the absence of hemorrhagic complications.

6 ACT, however, does not predict hemorrhagic complications.

7 tion but with higher risks of infectious and hemorrhagic complications.

8 ed their differential impact on ischemic and hemorrhagic complications.

9 erapy is often refrained from out of fear of hemorrhagic complications.

10 osage, anticoagulation control, and risk for hemorrhagic complications.

11 infection, but with more thromboembolic and hemorrhagic complications.

12 ing time (ACT) for prevention of ischemic or hemorrhagic complications.

13 nonfatal MI, rehospitalization, stroke, and hemorrhagic complications.

14 the potential for gastrointestinal upset and hemorrhagic complications.

15 ion is occasionally needed to treat or avoid hemorrhagic complications.

16 rombin have been anecdotally associated with hemorrhagic complications.

17 and 1 (4%) with a choroidal lesion suffered hemorrhagic complications.

18 of clotting factors, which may cause profuse hemorrhagic complications.

19 icial for patients with an increased risk of hemorrhagic complications.

20 model and were not associated with untoward hemorrhagic complications.

21 s, which are prone to bleed, causing serious hemorrhagic complications.

22 y performed because of the perceived risk of hemorrhagic complications.

23 dysfunction in EDS is likely contributing to hemorrhagic complications.

24 eplase results in similar outcomes but fewer hemorrhagic complications.

25 ced against a likelihood of developing major hemorrhagic complications.

26 nts receiving ECMO are at particular risk of hemorrhagic complications.

27 creased risk for mortality from ischemic and hemorrhagic complications.

28 with CKD are at high risk for thrombotic and hemorrhagic complications.

29 nherent risk of potential thromboembolic and hemorrhagic complications.

30 s randomized to the TriActiv System had more hemorrhagic complications (10.9% vs. 5.4%; p = 0.01).

31 ercent, P<0.001), but they had more frequent hemorrhagic complications (17 percent vs. 5 percent, P<0

32 In 8 patients, hemorrhagic complications (5 autoantibodies and 3 bovine

33 nts]; OR, 6.8; P = .004) and a lower rate of hemorrhagic complications (5.2% [five of 96 patients] vs

34 anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), ha

35 hrombosis (11%), venous thrombosis (7%), and hemorrhagic complications (8%).

36 patients with major bleeding or at risk for hemorrhagic complications, administration of platelet co

37 Hemorrhagic complications affect patient prognosis both

38 ction of CXCL13 and IL-6, and thrombotic and hemorrhagic complications affecting multiple organs with

39 With the exception of severe ischemic or hemorrhagic complications affecting the abdominal organs

40 al death and the development of ischemic and hemorrhagic complications and ICU-acquired infections.

41 rain injury (ABI) frequency, thrombotic, and hemorrhagic complications and mortality in COVID-19- vs.

42 The association between hemorrhagic complications and mortality may explain the

43 dural BP characteristics and recanalization, hemorrhagic complications and outcome in patients receiv

44 is markedly limited owing to concerns about hemorrhagic complications and the requirement that tPA b

45 Clinically significant hemorrhagic complications and thrombocytopenia were infr

46 ion of dabigatran to avoid the deaths due to hemorrhagic complications and thromboembolic stroke in c

47 Hemorrhagic complications and transfusion requirements w

48 No patient developed a significant hemorrhagic complication, and each patient's platelet co

49 cessful reperfusion, good clinical outcomes, hemorrhagic complications, and mortality.

50 ; p = 0.06), but COVID-19 patients had fewer hemorrhagic complications (aOR, 0.27; 95% CI, 0.17-0.42;

51 Hemorrhagic complications are frequently implicated clin

52 Thrombotic and hemorrhagic complications are prevalent in patients with

53 rently employed have encountered significant hemorrhagic complications, as well as complications from

54 educes both cerebrovascular permeability and hemorrhagic complications associated with late administr

55 t correlated with an increased occurrence of hemorrhagic complications, but bleeding complications di

56 The composite of hemorrhagic complications did not occur more often in th

57 It is characterized by severe hemorrhagic complications due in part to excessive fibri

58 Hemorrhagic complications during EUS-guided pseudocyst d

59 (8.7%) patients exhibited severe ischemic or hemorrhagic complications during the ICU stay.

60 nticoagulants, there is an increased risk of hemorrhagic complications for these men.

61 To discuss thrombotic and hemorrhagic complications from angiogenesis inhibitors a

62 ildren, sisters, both with severe, recurrent hemorrhagic complications from factor VII deficiency, su

63 Hemorrhagic complications from intracranial pressure mon

64 on is known to induce a prothrombotic state, hemorrhagic complications have also been reported in pat

65 Hemorrhagic complications have been strongly linked with

66 GIB is a potential hemorrhagic complication in patients with ACS treated wi

67 nor functioned adequately, and there were no hemorrhagic complications in any of the recipients.

68 ac performance with a low incidence of major hemorrhagic complications in patients with documented es

69 No threshold was found for hemorrhagic complications in patients with or without gl

70 milar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina

71 bin concentration, in reinterventions due to hemorrhagic complications, in the use of erythropoiesis-

72 Both ischemic and hemorrhagic complications increase mortality rate in acu

73 e its association with a higher frequency of hemorrhagic complications, intraarterial infusion of uro

74 ]; P < .001) and not significantly different hemorrhagic complications (OAC: 14/172 [8.1%] vs no OAC:

75 Significant hemorrhagic complications occur with living kidney donat

76 Hemorrhagic complications occurred in 10 patients (1.8 p

77 Major hemorrhagic complications occurred in 3 recipients, all

78 croL (platelets), no secondary infectious or hemorrhagic complications occurred.

79 possibility that rupture represents an early hemorrhagic complication of thrombolytic therapy should

80 ion of annexin II may be a mechanism for the hemorrhagic complications of APL.

81 tion of antiplatelet therapy and the risk of hemorrhagic complications of having a surgical procedure

82 To define hemorrhagic complications of living kidney donation, a s

83 of ocular complications, including uveitis, hemorrhagic complications, optic disc edema, and dry eye

84 Clinically, the dengue virus can cause hemorrhagic complications or ocular inflammation.

85 ion in mRS scores 0-2 (OR, 2.04; P = .45) or hemorrhagic complications (OR, 0.60; P = .63).

86 Hemorrhagic complication rates in pediatric stroke are u

87 Two patients (0.7%) had a hemorrhagic complication requiring transfusion, and anot

88 r hematocrit >5% in the first week after KT, hemorrhagic complications requiring surgery, and de novo

89 clinical guidelines to minimize the risk of hemorrhagic complications such as epidural hematoma.

90 al inflammation, leading to substantial post-hemorrhagic complications such as vasospasm and delayed

91 f stent thrombosis, although there were more hemorrhagic complications than with aspirin alone.

92 F) plays an important role in triggering the hemorrhagic complications that characterize EBOV infecti

93 Unlike major hemorrhagic complications, there is no evidence that the

94 Hemorrhagic complications were associated with an increa

95 e of symptomatic intracranial hemorrhage and hemorrhagic complications were classified based on the S

96 Hemorrhagic complications were infrequent, with no signi

97 Hemorrhagic complications were lower with the reduced-do

98 Hemorrhagic complications were noted, and the Fisher exa

99 Where data were available, hemorrhagic complications were rare in intracranial pres

100 Hemorrhagic complications were reported in 579 patients

101 No major hemorrhagic complications were reported.

102 disease and require ocular intervention for hemorrhagic complications when compared with matched pat

103 ation of vision, resolution of exudative and hemorrhagic complications with regression of polyps in p

104 Rates of hemorrhagic complications with the two drugs were simila

105 o suggest a higher risk of thromboembolic or hemorrhagic complications with use of dabigatran for per